Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Mar
21
Today In Oncology
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
Hypofractionated Locoregional RT in Early Breast Cancer
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
AMA Survey Finds Rapid Growth in Physician AI Adoption
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo